ERC Society for Endocrinology Archive
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Endocrine-Related Cancer 13 (2) 293 -325     DOI: 10.1677/erc.1.01172
Copyright © 2006 by the Society for Endocrinology
This Article
Right arrow Free Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lacroix, M.
Right arrow Articles by Leclercq, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lacroix, M.
Right arrow Articles by Leclercq, G.
REVIEW

p53 and breast cancer, an update

Marc Lacroix, Robert-Alain Toillon and Guy Leclercq

Laboratoire Jean-Claude Heuson de Cancérologie Mammaire, Institut Jules Bordet – Université Libre de Bruxelles, 127 boulevard de Waterloo, B-1000 Bruxelles, Belgium

(Requests for offprints should be addressed to M Lacroix; Email: Marc.Lacroix{at}ulb.ac.be)

p53 plays a key role in mediating cell response to various stresses, mainly by inducing or repressing a number of genes involved in cell cycle arrest, senescence, apoptosis, DNA repair, and angiogenesis. According to this important function, p53 activity is controlled in a very complex manner, including several auto-regulatory loops, through the intervention of dozens of modulator proteins (the ‘p53 interactome’). p53 mutations are observed in a significant minority of breast tumours. In the remaining cases, alterations of interactome components or target genes could contribute, to some extent, to reduce the ability of p53 to efficiently manage stress events. While the prognostic and predictive value of p53 is still debated, there is an increasing interest for p53-based therapies. The present paper aims to provide updated information on p53 regulation and function, with specific interest on its role in breast cancer.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
F. Song, H. Zheng, B. Liu, S. Wei, H. Dai, L. Zhang, G. A. Calin, X. Hao, Q. Wei, W. Zhang, et al.
An miR-502-Binding Site Single-Nucleotide Polymorphism in the 3'-Untranslated Region of the SET8 Gene Is Associated with Early Age of Breast Cancer Onset
Clin. Cancer Res., October 1, 2009; 15(19): 6292 - 6300.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Keimling and L. Wiesmuller
DNA double-strand break repair activities in mammary epithelial cells--influence of endogenous p53 variants
Carcinogenesis, July 1, 2009; 30(7): 1260 - 1268.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
Y.-C. Hwang, T.-Y. Lu, D.-Y. Huang, Y.-S. Kuo, C.-F. Kao, N.-H. Yeh, H.-C. Wu, and C.-T. Lin
NOLC1, an Enhancer of Nasopharyngeal Carcinoma Progression, Is Essential for TP53 to Regulate MDM2 Expression
Am. J. Pathol., July 1, 2009; 175(1): 342 - 354.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C. Lanari, C. A Lamb, V. T Fabris, L. A Helguero, R. Soldati, M. C. Bottino, S. Giulianelli, J. P. Cerliani, V. Wargon, and A. Molinolo
The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer
Endocr. Relat. Cancer, June 1, 2009; 16(2): 333 - 350.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Saramaki, S. Diermeier, R. Kellner, H. Laitinen, S. Vaisanen, and C. Carlberg
Cyclical Chromatin Looping and Transcription Factor Association on the Regulatory Regions of the p21 (CDKN1A) Gene in Response to 1{alpha},25-Dihydroxyvitamin D3
J. Biol. Chem., March 20, 2009; 284(12): 8073 - 8082.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
I. Benakanakere, C. Besch-Williford, M. R Ellersieck, and S. M Hyder
Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study
Endocr. Relat. Cancer, March 1, 2009; 16(1): 85 - 98.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
J. J. Manfredi
Insights from a novel p53 isoform in zebrafish want to reel us in, but will we take the bait?
Genes & Dev., February 1, 2009; 23(3): 261 - 264.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Naiki-Ito, M. Asamoto, N. Hokaiwado, S. Takahashi, H. Yamashita, H. Tsuda, K. Ogawa, and T. Shirai
Gpx2 Is an Overexpressed Gene in Rat Breast Cancers Induced by Three Different Chemical Carcinogens
Cancer Res., December 1, 2007; 67(23): 11353 - 11358.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Sayeed, S. D. Konduri, W. Liu, S. Bansal, F. Li, and G. M. Das
Estrogen Receptor {alpha} Inhibits p53-Mediated Transcriptional Repression: Implications for the Regulation of Apoptosis
Cancer Res., August 15, 2007; 67(16): 7746 - 7755.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Bartsch, C. Wenzel, G. Altorjai, U. Pluschnig, R. M. Mader, M. Gnant, R. Jakesz, M. Rudas, C. C. Zielinski, and G. G. Steger
Her2 and Progesterone Receptor Status Are Not Predictive of Response to Fulvestrant Treatment
Clin. Cancer Res., August 1, 2007; 13(15): 4435 - 4439.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. Lacroix
Significance, detection and markers of disseminated breast cancer cells
Endocr. Relat. Cancer, December 1, 2006; 13(4): 1033 - 1067.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Society for Endocrinology.